Summary
The product DHB 100 mg (1-Testosterone Cypionate), manufactured by Olympian Pharmaceutical, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 0069, was submitted by Olympian Pharmaceutical and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of 1-Testosterone Cypionate, with a concentration of 101.77 mg/ml, which is 1.77% above the labeled claim of 100 mg/ml.
The testing process began on 24 October 2024, with the sample received on 30 October 2024, and analysis completed on 01 November 2024. The results confirm the presence of the active ingredient, with the measured concentration being highly accurate. Independent third-party testing remains essential to validate these findings and ensure consistency across different batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Olympian Pharmaceutical
- Product Name: DHB 100 mg
- Active Ingredient: 1-Testosterone Cypionate
- Batch Number: 0069
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #51790
- Testing Ordered: 24 October 2024
- Sample Received: 30 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Olympian Pharmaceutical (Manufacturer)
- Analysis Paid For By: Olympian Pharmaceutical (Manufacturer)
Testing Results
- Specification: 100 mg/ml (as stated on the label)
- Measured Concentration: 101.77 mg/ml
- Accuracy: 101.77% (1.77% above the label claim)
Verification Details
Verification URL: https://janoshik.com/tests/51790_X3NZRMRHTE8U
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that DHB 100 mg is accurately dosed, with a measured concentration of 101.77 mg/ml, which is 1.77% above the labeled claim. This result demonstrates high consistency in formulation and quality. Since Olympian Pharmaceutical submitted and funded the test, independent validation through third-party testing remains crucial to confirm product uniformity across different batches.
Conclusion
The analysis confirms that DHB 100 mg is precisely dosed, with a measured concentration of 101.77 mg/ml, which is 1.77% above the labeled claim. The presence of the active ingredient is verified, and the result demonstrates high accuracy. This underscores the importance of continued testing to maintain high product standards. This report is provided as an educational and harm reduction resource, helping consumers make informed choices regarding steroid-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it provides useful data when critically assessed alongside third-party independent results. Readers are encouraged to use this information responsibly.
